NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia

CompletedN/A

Sponsor: Sanofi

Conditions: Epilepsy, Seizures

Interventions: Sodium valporate

Countries: France

A cross-sectional, national, multicenter, survey-based study to assess the effectiveness of Risk Minimization Measures related to Depakine® (sodium valproate) in Saudi Arabia. The end of study is defined as the end of the data collection period. No intervention will be administered, and no study related visits are required.

Eligibility overview

Sex: ALL

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Healthcare professionals working only in Saudi Arabia AND
* Prescribers of Depakine® (sodium valiporate) at least once in the six months leading up to survey completion OR
* Obstetricians/Gynecologists who consulted at least one women of childbearing potential treated with Depakine® (sodium valproate) in the six months leading up to survey completion OR
* Pharmacists who have dispensed Depakine® (sodium valproate) in the six months leading up to survey completion

Exclusion Criteria:

* Healthcare professionals who may have conflicts of interest with the survey (i.e. employed by regulatory bodies or pharmaceutical companies)
* Healthcare professionals (or with a relative) involved in valproate-related lawsuits or associations for victims of valproate syndrome
* Healthcare professionals who are not prescribing Depakine® (sodium valproate), except for obstetricians/gynecologists (who do not prescribe Depakine® \[sodium valproate\])
* Healthcare professionals having started to prescribe or dispense Depakine® (sodium valproate) earlier than six months before survey completion

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Locations (1)

Chilly-Mazarin, France